Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + anlotinib + taxane-based chemotherapy
- Development stage
- Unknown
- Lead developer
- Innovent Biologics Technology Limited (Shanghai R&D Center)
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Sintilimab + anlotinib + taxane-based chemotherapy is an investigational combination regimen being evaluated for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC). The regimen combines three distinct therapeutic approaches: immune checkpoint blockade, anti-angiogenesis, and cytotoxic chemotherapy. Sintilimab is a fully human IgG4 monoclonal antibody that targets the PD-1 receptor, preventing its interaction with PD-L1 and PD-L2 to reactivate anti-tumor T-cell responses. Anlotinib is an oral, small-molecule multi-target tyrosine kinase inhibitor that suppresses tumor growth and angiogenesis by inhibiting VEGFR, FGFR, PDGFR, and c-Kit. The taxane component (typically paclitaxel or docetaxel) acts as a microtubule stabilizer, interfering with cell division and inducing apoptosis. This triple combination is primarily being studied in patients who have progressed after prior platinum-based chemotherapy or immunotherapy.
- Brand names
- Fuqila
- Other names
- sintilimab plus anlotinib plus taxane
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRB (Platelet-derived growth factor receptor beta)PDGFRA (Platelet-derived growth factor receptor alpha)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on sintilimab + anlotinib + taxane-based chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + anlotinib + taxane-based chemotherapy.